Tevis Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Tevis Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,010	Closed	-$407K	–	110
2025 Q1	$407K	Hold	1,010	–	–	0.3%	75
2024 Q4	$407K	Sell	1,010 -32	-3%	-$14.8K	0.3%	75
2024 Q3	$485K	Buy	1,042 +191	+22%	+$91.8K	0.36%	66
2024 Q2	$399K	Sell	851 -24	-3%	-$10.4K	0.32%	71
2024 Q1	$366K	Buy	875 +79	+10%	+$33.4K	0.31%	72
2023 Q4	$324K	Sell	796 -55	-6%	-$20.3K	0.3%	75
2023 Q3	$296K	Buy	+851	New	+$298K	0.3%	75

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Tevis Investment Management's VRTX Position: Q2 2025 in Review

Tevis Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 1,010 shares — an estimated $407K sold.

Tevis Investment Management first reported a position in VRTX in Q3 2023 and held it in 7 quarters. The position peaked at $485K in Q3 2024. 1,563 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

Tevis Investment Management reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Tevis Investment Management sold 1,010 Vertex Pharmaceuticals shares in Q2 2025, an estimated $407K.
Tevis Investment Management first reported a position in Vertex Pharmaceuticals in Q3 2023 and held it in 7 quarters.
Tevis Investment Management's Vertex Pharmaceuticals position peaked at $485K in Q3 2024.
1,563 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Tevis Investment Management's 13F filing for Q2 2025, filed 1 Aug 2025.